<DOC>
	<DOCNO>NCT00038805</DOCNO>
	<brief_summary>Primary Objective : To determine safety maximum tolerate dose CMA-676 part intensive nonmyeloablative preparative regimen older medically infirm patient undergo mini-allogeneic peripheral blood stem cell transplantation Secondary Objectives : 1 . To evaluate response rate , engraftment kinetics degree chimerism achievable strategy . 2 . To evaluate disease-free overall survival relapse rate . 3 . To evaluate need ability give multiple cycle Mylotarg plus FA mobilize DLI patient achieve complete remission .</brief_summary>
	<brief_title>Nonmyeloablative Preparative Regimen Using Mylotarg Patients With High Risk Acute Myeloid Leukemia ( AML ) , Acute Lymphocytic Leukemia ( ALL ) , Chronic Myeloid Leukemia ( CML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Mylotarg novel immunoconjugate direct CD33 antigen find leukemia cell . This humanized murine IgG4 monoclonal antibody tag toxin , calicheamicin . In equal molar concentration , calicheamicin 3200 time potent adriamycin . In Phase I study involve adult patient relapse AML , Mylotarg show significant anti-leukemia activity little toxicity . The concern side effect Mylotarg prolong neutropenia thrombocytopenia . Phase II study also demonstrate good efficacy little toxicity . The goal proposal include Mylotarg nonmyeloablative preparative regimen similar FAI use MD Anderson Cancer Center . The hypothesis Mylotarg provide potent anti-leukemic effect without add toxicity mini-allogeneic bone marrow transplant regimen . A potent anti-leukemic response may increase complete remission rate induce state minimal residual disease ( MRD ) . Therefore , Graft vs. Leukemia ( GVL ) effect allogeneic transplantation well chance success . In addition , administration donor cell Mylotarg ameliorate cytopenia previously associate Mylotarg . This medication likely well-tolerated . Patients high-risk hematopoietic malignancy express CD33 ( i.e . AML , ALL , CML MDS ) include . We enroll old patient ( &gt; 55 year old ) medically infirm patient unable tolerate standard allogeneic bone marrow transplant . Patients evaluate 28 day post-transplant evidence response . Those residual disease may eligible additional Mylotarg give together donor lymphocyte infusion . Additional course Mylotarg may improve overall survival poor prognosis group .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Patients 1275 year age Patients eligible deem ineligible conventional high dose chemotherapy program concurrent medical condition . Patients refractory AML eligible provide ejection fraction &gt; = 35 % ; FEV1 , FVC , DLCO &gt; = 40 % ; GPT &lt; 3 x normal , direct bilirubin &lt; 2 . Patients must recover previous Grade IIIIV toxicity due prior antineoplastic therapy ( except alopecia ) . Patients AML induction failure , relapse 2nd remission Patients MDS IPI INT2 Highrisk disease CMML . Patients CML accelerate phase blast crisis Patients ALL induction failure , relapse 2nd remission Patients receive prior BMT eligible . If myeloablative chemoradiotherapy use prior transplant patient must &gt; 90 day transplant . If nonmyeloablative therapy use patient must &gt; 30 day posttransplant . Leukemia cell must express cell surface CD33 evaluate flow cytometry &gt; 20 % leukemia cell . Patients must HLA identical relate donor capable donate GCSF stimulate peripheral blood stem cell use apheresis technique . If patient contraindication PBSC collection bone marrow use . Patients must Zubrod PS &lt; 2 , Cr &lt; 2.0 , direct bilirubin &lt; 2 , transaminase SGPT &lt; 3x normal Patients must estimate life expectancy &gt; 3 month Patient donor must sign informed consent uncontrolled active infection HIV disease pregnancy nurse active , uncontrolled CNS leukemia</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>High Risk Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphocytic Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>CML</keyword>
	<keyword>CMML</keyword>
	<keyword>Nonmyeloablative Preparative Regimen</keyword>
	<keyword>Mylotarg</keyword>
	<keyword>CMA-676</keyword>
</DOC>